Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

Posted on by

CHENGDU, China, June 2, 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis (AD) has been released by way of oral…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.